Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids.

导出 LinkOut

翻译打印收藏纠错

作者： Rei,Yamaguchi ^[1] ; Eiichi,Tanaka ^[2] ; Ayako,Nakajima ^[1] ; Eisuke,Inoue ^[2] ; Mai,Abe ^[1] ; Eri,Sugano ^[3] ; Naohiro,Sugitani ^[1] ; Kumiko,Saka ^[4] ; Moeko,Ochiai ^[1] ; Yoko,Higuchi ^[2] ; Naoki,Sugimoto ^[1] ; Katsunori,Ikari ^[2] ; Hisashi,Yamanaka ^[1] ; Masayoshi,Harigai ^[2]

作者单位： Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan. ^[1] Department of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University Hospital, Tokyo, Japan. ^[2] Center for Rheumatic Disease, Mie University Hospital, Mie, Japan. ^[3] Research Administration Center, Showa University, Tokyo, Japan. ^[4] Department of Orthopedic Surgery, Institute of Rheumatology, Tokyo Women's Medical University Hospital, Tokyo, Japan. ^[5] Division of Multidisciplinary Management of Rheumatic Diseases, Department of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan. ^[6] Rheumatology, Sanno Medical Center, Tokyo, Japan. ^[7] Department of Rheumatology, International University of Health and Welfare, Tokyo, Japan. ^[8]

关键词 Biologic disease-modifying antirheumatic drug corticosteroid herpes zoster methotrexate rheumatoid arthritis